Business Context and Reporting Period
Company: Pavmed Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 25, 2021
Event: Closing of an underwritten public offering of common stock.
Key Financial Metrics
The filing details a capital raise event rather than operational financial performance. Key figures include:
- Shares Sold: 9,782,609 shares of common stock.
- Net Proceeds: Approximately $41.2 million.
- Offering Expenses: Approximately $0.4 million (excluding underwriter discounts and commissions).
- Underwriter: Cantor Fitzgerald & Co. (Sole book-running manager).
Note: The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in the company's cash liquidity resulting from the closing of the offering. The transaction was executed pursuant to existing shelf registration statements (Nos. 333-248709 and 333-253384).
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard disclosure of the offering mechanics. The company is identified as an "emerging growth company."
Investor Verification Checklist
- Verify the use of the $41.2 million in net proceeds as described in the accompanying press release (Exhibit 99.1).
- Confirm the dilution impact of the 9,782,609 newly issued shares on existing shareholders.
- Review the full prospectus supplement filed on February 23, 2021, for detailed terms of the offering.
- Check subsequent filings for updates on the company's cash runway and operational milestones.